There are currently 37 ongoing clinical trials involving Hairy Cell Leukemia
Of the 37 trials,17 trials are in Phase II
Furthermore, 12 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Hairy Cell Leukemia, an oncology condition. The largest number of ongoing clinical trials for Hairy Cell Leukemia is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Hairy Cell Leukemia-related drug trials.
National Cancer Institute US: The leading ongoing Hairy Cell Leukemia related clinical trial sponsor
National Cancer Institute US is the top sponsor for Hairy Cell Leukemia-related ongoing clinical trials.
City of Hope. Affiliated Hospital of Xuzhou Medical University, Memorial Sloan Kettering Cancer Center, and Tongji Hospital among other notable clinical trial sponsors involved in Hairy Cell Leukemia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Hairy Cell Leukemia
Moxetumomab pasudotox (Lumoxiti), Recombinant human interferon alpha-2a (Intefen, Interfen), and Interferon alpha 2b (Intron A, IntronA, Viraferon) are among the key marketed drugs involving Hairy Cell Leukemia.
Moxetumomab pasudotox (Lumoxiti) is a derivative of pseudomonas exotoxin, acts as an anti-neoplastic agent. It functions via Cytotoxic To Cells Expressing B Cell Receptor CD22 (B Lymphocyte Cell Adhesion Molecule or Sialic Acid Binding Ig Like Lectin 2 or T Cell Surface Antigen Leu 14 or CD22) mechanism of action. It is formulated as powder for solution for intravenous route of administration. Lumoxiti is marketed for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Moxetumomab pasudotox was first approved in 2018 and is marketed globally including the US, Germany, and France by several pharma giants including AstraZeneca Plc, and Innate Pharma Inc.
Recombinant human interferon alpha-2a (Intefen, Interfen) is a broad-spectrum antitumor, antiviral and immuno-regulatory agent. It functions via Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) Agonist; Interferon Alpha/Beta Receptor 2 (Interferon Alpha Binding Protein or Type I Interferon Receptor 2 or IFNAR2) Agonist mechanism of action. It is formulated as solution for intramuscular and subcutaneous administration. Interfen is indicated for the treatment of acute and chronic hepatitis C, chronic active hepatitis B, genital warts, hairy cell leukemia, and rare blood and bone marrow cancers. Recombinant human interferon alpha-2a was first approved in 1995 and is marketed in China by 3SBio Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer